content=["<dl>",
"<dt><a href='#Section0'>Familial medullary thyroid cancer</a></dt>",
"<dd id='Section0'>",
"<p><strong>Sign & Symptoms:</strong> Negative family history of MEN syndrome.Multiple family members &gt;50 years of age are affected by medullary thyroid cancer without phaeochromocytoma.",
"<br><strong>Test:</strong> Specific RET proto-oncogene mutations for familial medullary thyroid cancer (FMTC). [27]</p>",
"</dd>",
"<dt><a href='#Section1'>Hyperparathyroidism-jaw tumour syndrome</a></dt>",
"<dd id='Section1'>",
"<p><strong>Sign & Symptoms:</strong> Strong family history of hyperparathyroidism-jaw tumour syndrome.Parathyroid carcinoma develops in 10% to 15% of affected patients.",
"<br><strong>Test:</strong> Raised calcium levels (can be in the range of 3.25-3.5 mmol/L [13-14 mg/dL]).Genetic testing for HRPT2 gene germline mutations. [52]</p>",
"</dd>",
"<dt><a href='#Section2'>Isolated familial hyperparathyroidism</a></dt>",
"<dd id='Section2'>",
"<p><strong>Sign & Symptoms:</strong> Negative family history of MEN1. [53]However, up to 20% of families with isolated familial hyperparathyroidism (IFHPT) do have MEN1 gene mutations, which suggests modifying genetic factors may be protecting those families against other MEN1 tumours. [1]",
"<br><strong>Test:</strong> Genetic testing for MEN1 gene mutations. However, this may be insufficiently sensitive, meaning patients require continued monitoring for late appearances of non-parathyroid tumours characteristic of MEN1.</p>",
"</dd>",
"<dt><a href='#Section3'>Sporadically occurring primary hyperparathyroidism</a></dt>",
"<dd id='Section3'>",
"<p><strong>Sign & Symptoms:</strong> Age of onset for sporadic cases is up to 30 years later than for MEN1. [54]",
"<br><strong>Test:</strong> MEN screening (performed if unusual features exist, e.g., family history, young age at presentation.)</p>",
"</dd>",
"<dt><a href='#Section4'>Familial hypocalciuric hypercalcaemia</a></dt>",
"<dd id='Section4'>",
"<p><strong>Sign & Symptoms:</strong> Positive family history.Generally asymptomatic.",
"<br><strong>Test:</strong> Calcium clearance to creatinine clearance ratio &lt;0.01 (tested when vitamin D replete and in the absence of interfering medications, such as thiazide diuretics).Lifelong elevated serum calcium levels in index cases and family members.Parathyroid hormone may be elevated.</p>",
"</dd>",
"<dt><a href='#Section5'>Isolated familial pituitary tumours</a></dt>",
"<dd id='Section5'>",
"<p><strong>Sign & Symptoms:</strong> Usually familial somatotropinomas that are distinguished from sporadic acromegaly by positive family history. [55]",
"<br><strong>Test:</strong> Genetic testing may reveal mutations in arylhydrocarbon receptor-interacting protein genes (found in some families with isolated pituitary tumours).</p>",
"</dd>",
"<dt><a href='#Section6'>Carney's complex</a></dt>",
"<dd id='Section6'>",
"<p><strong>Sign & Symptoms:</strong> Spotty skin pigmentation, cardiac myxomas, and pigmented adrenal cortical hyperplasia. [56]Abnormal skin pigmentation may be the first sign at birth. Lentigines usually assume their characteristic distribution later.Related cardiac myxoma signs and symptoms include symptoms of right or left ventricular failure, syncope, haemoptysis, Raynaud's phenomenon, murmurs, elevated jugular venous pressures, and/or pyrexia.",
"<br><strong>Test:</strong> Genetic testing may reveal inactive mutations in the gene encoding for protein kinase A type 1A regulatory subunits (present in &gt;60% of patients). [57]</p>",
"</dd>",
"</dl>"].join("\n");